Checkpoint Therapeutics Inc Net Income per Employee (CKPT), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Checkpoint Therapeutics inc   (NASDAQ: CKPT)
 

Checkpoint Therapeutics Inc Net Income per Employee

CKPT's Quarterly Results, Trends, Rankings, Statistics
Checkpoint Therapeutics Inc recorded a cumulative net loss of $-57 million during 12 month ending in the first quarter 2025.
The Healthcare sector has seen employees of 432 other companies achieving higher income per employee. While Checkpoint Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3492 to 4344.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CKPT Net Income per Employee (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,974,053 -2,960,000 -2,445,684 -2,235,105 -2,753,579
CKPT's Total Ranking # 4344 # 3492 # 2883 # 3141 # 2324
Seq. Net Income Change - - - - -

CKPT Company Profile >> Back to CKPT Efficiency Comparisons >> Compare CKPT Net Income per Employee to its Competitors

CKPT Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 912
Overall Market # 4344

Net Income per Employee Statistics
High Average Low
$ -230,684 $ -2,145,203 $ -4,109,737
(Mar 31 2017)   (Jun 30 2022)




  News about Checkpoint Therapeutics inc Income per employee

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market: Funding Boost for Promising Immunotherapy and Targeted Oncology Research

Checkpoint Therapeutics Inc., a clinical-stage immunotherapy and targeted oncology company, has recently made an exciting announcement regarding its latest financial development. The company has officially entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of 7,756,233 shares of its common stock at a purchase price of $1.805 per share. This registered direct offering priced at-the-market is expected to raise a total of $14 million.
Furthermore, in a concurrent private placement, Checkpoint will also issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock. These warrants will have an exercise price of $1.68 per share and will be immediately exercisable upon issuance, with an expiration date set for five years following the issuance date.




Companies with similar Income per Employee for 12 month ending Mar 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2025Number of Employees Mar 31 2025


Date modified: 2026-06-22T14:32:40+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.